How Does Protective Type2 Immunity Become Harmful Type2Inflammation?
Dermatology
In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type2 immunity can become dysregulated, leading to harmful type2inflammation.
Inside the Hive: Type2 Inflammatory Pathways in Chronic Spontaneous Urticaria
Dermatology
Join Dr. Jason Hawkes in discussing the burden of CSU and how type2inflammation contributes to the development of chronic wheals (hives) and angioedema
Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
